Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC).

Abstract

BACKGROUND:

Raf-1 kinase inhibitor protein (RKIP) has emerged as a significant metastatic suppressor in a variety of human cancers and is known to inhibit Ras/Raf/MEK/ERK signaling. By suppressing the activation of the NFkB/SNAIL circuit, RKIP can regulate the induction of epithelial-mesenchymal transition (EMT). The aim of this study was to evaluate RKIP expression and to determine its association with clinicopathological features, including EMT in form of tumor budding in pancreatic ductal adenocarcinoma (PDAC).

METHODS:

Staining for RKIP was performed on a multipunch Tissue Microarray (TMA) of 114 well-characterized PDACs with clinico-pathological, follow-up and adjuvant therapy information. RKIP-expression was assessed separately in the main tumor body and in the tumor buds. Another 3 TMAs containing normal pancreatic tissue, precursor lesions (Pancreatic Intraepithelial Neoplasia, PanINs) and matched lymph node metastases were stained in parallel. Cut-off values were calculated by receiver operating characteristic (ROC) curve analysis.

RESULTS:

We found a significant progressive loss of RKIP expression between normal pancreatic ductal epithelia (average: 74%), precursor lesions (PanINs; average: 37%), PDAC (average 20%) and lymph node metastases (average 8%, p<0.0001). RKIP expression was significantly lower in tumor buds (average: 6%) compared to the main tumor body (average 20%; p<0.005). RKIP loss in the tumor body was marginally associated with advanced T-stage (p=0.0599) as well as high-grade peritumoral (p=0.0048) and intratumoral budding (p=0.0373). RKIP loss in the buds showed a clear association with advanced T stage (p=0.0089).

CONCLUSIONS:

The progressive loss of RKIP seems to play a major role in the neoplastic transformation of pancreas, correlates with aggressive features in PDAC and is associated with the presence of EMT in form of tumor budding.

• Authors: Eva Karamitopoulou, Inti Zlobec, Beat Gloor, Agathi Kondi-Pafiti, Alessandro Lugli, Aurel Perren
• Journal: Journal of translational medicine (J Transl Med) Vol. 11 Pg. 311 (Dec 14 2013) ISSN: 1479-5876 [Electronic] England
• PMID: 24330423 (Publication Type: Journal Article)

Chemical References

• PEBP1 protein, human
• Phosphatidylethanolamine Binding Protein

Topics

• Adenocarcinoma (enzymology, genetics, pathology)
• Adult
• Aged
• Aged, 80 and over
• Carcinoma, Pancreatic Ductal (enzymology, genetics, pathology)
• Female
• Humans
• Male
• Middle Aged
• Pancreatic Neoplasms (enzymology, genetics, pathology)
• Phosphatidylethanolamine Binding Protein (genetics, physiology)